AR053046A1 - Cristal de derivado de aminonopirrolidina y metodo de produccion del mismo - Google Patents

Cristal de derivado de aminonopirrolidina y metodo de produccion del mismo

Info

Publication number
AR053046A1
AR053046A1 ARP060101363A ARP060101363A AR053046A1 AR 053046 A1 AR053046 A1 AR 053046A1 AR P060101363 A ARP060101363 A AR P060101363A AR P060101363 A ARP060101363 A AR P060101363A AR 053046 A1 AR053046 A1 AR 053046A1
Authority
AR
Argentina
Prior art keywords
crystal
aminonopirrolidine
derivative
same
production method
Prior art date
Application number
ARP060101363A
Other languages
English (en)
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36607292&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR053046(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of AR053046A1 publication Critical patent/AR053046A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Reivindicacion 2: Un cristal (R)-3-[2-(2-amino-5-trifluormetoxibenzamido)acetamida]-1-(6-metilindol-3-ilmetil)pirrolidina (cristal A) que exhibe un patron de difraccion de polvo de rayos X que tiene picos característicos expresados en el ángulo de reflexion 20(grado) en aproximadamente 5,7; 8,4; 15,2; 16,9; 19,7; 20,9; 21,3; 21,7 y 24,1. Reivindicacion 4: Un cristal de (R)-3-[2-(2-amino-5-trifluormetoxibenzamido) acetamido]-1-(6-metilindol-3-ilmetil)pirrolidina (cristal B) que . exhibe un patron de difraccion de polvo de rayos X que tiene picos característicos expresados en el ángulo de reflexion 20 (grado) en aproximadamente 9,6; 11,3; 15,5; 16,3; 19,3; 20,0; 20,5; 20,9; 22,7; 23,3; 24,2; 27,2; 27,8 y 31,6. Su forma amorfa, una composicion farmacéutica que contiene el cristal o la forma amorfa como un ingrediente activo, así como también métodos para su preparacion.
ARP060101363A 2005-04-07 2006-04-06 Cristal de derivado de aminonopirrolidina y metodo de produccion del mismo AR053046A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005110854 2005-04-07

Publications (1)

Publication Number Publication Date
AR053046A1 true AR053046A1 (es) 2007-04-18

Family

ID=36607292

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101363A AR053046A1 (es) 2005-04-07 2006-04-06 Cristal de derivado de aminonopirrolidina y metodo de produccion del mismo

Country Status (13)

Country Link
US (1) US20090076120A1 (es)
EP (1) EP1871767A1 (es)
JP (1) JP2008534436A (es)
KR (1) KR20070116863A (es)
CN (1) CN101155802A (es)
AR (1) AR053046A1 (es)
AU (1) AU2006234545A1 (es)
BR (1) BRPI0609739A2 (es)
CA (1) CA2608078A1 (es)
PE (1) PE20061375A1 (es)
RU (1) RU2007141206A (es)
TW (1) TW200708512A (es)
WO (1) WO2006109836A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008156781A1 (en) * 2007-06-21 2008-12-24 Actimis Pharmaceuticals, Inc. Amine salts of a crth2 antagonist
EP2322499A4 (en) 2008-08-07 2011-12-21 Kyorin Seiyaku Kk PROCESS FOR PRODUCING A BICYCLOÝ2.2.2¨OCTYLAMINE DERIVATIVE
TW201016675A (en) * 2008-09-16 2010-05-01 Mitsubishi Tanabe Pharma Corp Crystalline benzoimidazole compound and salt thereof
CA2737296A1 (en) * 2008-09-16 2010-03-25 Kyorin Pharmaceutical Co., Ltd. Method for purifying aminoacetylpyrrolidinecarbonitrile derivative and salt thereof
TWI646091B (zh) * 2012-12-28 2019-01-01 日商衛斯克慧特股份有限公司 鹽類及晶形
GB201420285D0 (en) * 2014-11-14 2014-12-31 Bergenbio As Process

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069432A1 (fr) * 1999-05-18 2000-11-23 Teijin Limited Moyens de traitement et de prevention contre les maladies associees a des chimiokines
US20070073064A1 (en) * 2003-10-08 2007-03-29 Teijin Pharma Limited Method for producing aminopyrrolidine derivatives and intermediate compounds
JP2005112787A (ja) * 2003-10-08 2005-04-28 Teijin Pharma Ltd アミノピロリジン誘導体の製造法
AU2005252112A1 (en) * 2004-06-14 2005-12-22 Teijin Pharma Limited Method for producing acetamidopyrrolidine derivative and intermediate compound thereof

Also Published As

Publication number Publication date
CN101155802A (zh) 2008-04-02
US20090076120A1 (en) 2009-03-19
PE20061375A1 (es) 2007-01-23
WO2006109836A1 (en) 2006-10-19
BRPI0609739A2 (pt) 2011-10-18
JP2008534436A (ja) 2008-08-28
AU2006234545A1 (en) 2006-10-19
TW200708512A (en) 2007-03-01
EP1871767A1 (en) 2008-01-02
KR20070116863A (ko) 2007-12-11
RU2007141206A (ru) 2009-05-20
CA2608078A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
AR087208A2 (es) FORMA CRISTALINA DE 1-CLORO-4-(b-D-GLUCOPIRANOS-1-IL)-2-[4-((S)-TETRAHIDROFURAN-3-ILOXI)-BENCIL]-BENCENO, UN METODO PARA SU PREPARACION Y EL USO DEL MISMO PARA PREPARAR MEDICAMENTOS
CL2011000101A1 (es) Compuestos derivados de piridazina sustituida; inhibidores de la señalizacion hedgehog y smo; composicion farmaceutica; y uso para el tratamiento de trastornos o sindromes asociados con enfermedades hiperproliferativas.
AR053046A1 (es) Cristal de derivado de aminonopirrolidina y metodo de produccion del mismo
CU23616B7 (es) Forma cristalina gamma del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
IL193467A0 (en) Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
NO20082793L (no) Nye tiofenderivater
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
CL2011001098A1 (es) Compuestos derivados de 4-fluoro-1h-isoindol-3-amina; inhibidores de b-secretasa (bace); composicion farmaceutica; y su uso para el tratamiento o prevencion de una patologia relacionada con la proteina beta amiloide tal como sindrome de down, alzheimer, demencia senil y demencia asociada con parkinson, entre otras.
CL2010001406A1 (es) Composicion farmaceutica oftalmica que comprende povidona yodada, y un compuesto antiinflamatorio esteroidal, un compuesto antiinflamatorio no esteroidal, un antibacteriano, un antialergico o un compuesto antiglaucoma; y metodo para preservar la composicion.
BRPI0815134A2 (pt) Processo para a preparação de olmesartana medoxomila
CL2005003456A1 (es) Proceso de preparacion del beta-anomero enriquecido de clorhidrato de gemcitabina; compuesto intermediario involucrado en dicho proceso; y su proceso de preparacion.
WO2006105538A3 (en) Methods and compositions for treating il-21 related pathologies
CY1118976T1 (el) Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης
BRPI0815493A2 (pt) Composto, uso de um composto, composição faramcêutica, método para a terapia de dor, e, processo para preparar um composto.
AR074350A1 (es) Forma cristalina de un compuesto de 4-(2-(2- fluorofenoximetil) fenil ) pipiridina
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
ITMI20051630A1 (it) Formulazione farmaceutica sterile iniettabile contenente almeno due principi attivi
WO2009120389A8 (en) Oral and injectable formulations of tetracycline compounds
UY31758A (es) Forma cristalina anhidra de maleato de orvepitant
WO2009022327A3 (en) Novel process for preparing highly pure levocetirizine and salts thereof
CL2008001043A1 (es) Forma amorfa y cristalina de la oxima de la e-1-(4-((1r,2s,3r)-1,2,3,4-tetrahidroxibutil)-1h-imidazol-2-il)-etanona; composicion farmaceutica; y uso para tratar, controlar o prevenir una enfermedad o un trastorno autoinmune o inflamatorio.
ECSP077263A (es)
AR065565A1 (es) Formas solidas de 1-metil-5-(2-(5-(trifluoro-metil)-1h-imidazol-2-il)-piridin-4-iloxi)-n-(4-(trifluoro-metil)-fenil)-1h-benzo-[d]-imidazol-2-amina con actividad inhibidora de cinasa raf y una composicion farmaceutica que las comprende.
MX2019001771A (es) Composición farmacéutica sólida que comprende el sofosbuvir amorfo.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal